We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Two leaders of insulin made in China, Tonghua Dongbao and Gan & Lee Pharmaceuticals, has announced their performance in 2022 respectively. As the first year of centralized procurement of insulin, two companies' performance both declined in 2022.